

# Result of AGM

RNS Number : 4466R

Novacyt S.A.

26 October 2023

Novacyt S.A.

("Novacyt", the "Company" or the "Group")

## Result of AGM

Paris, France, and Eastleigh UK - 26 October 2023 - Novacyt S.A. (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that all resolutions proposed at the ordinary general meeting part of the Company's Annual General Meeting (AGM), held today, were duly passed.

As part of the AGM, the Company also met today to hold an extraordinary general meeting. The meeting was not deemed quorate due to the minimum number of voting rights under French company law not being present or represented at the meeting. Consequently, the meeting did not take place.

Following the AGM, Dr John Brown CBE and Lyn Rees have now formally joined the Novacyt Board, as Non-Executive and Executive Director respectively.

The results of the AGM voting will be made available on the Company's website.

## Contacts

Novacyt SA	+44 (0)23 8074 8830
------------	---------------------

James Wakefield, Non-Executive Chairman James McCarthy, Acting Chief Executive Officer	
---	--

SP Angel Corporate Finance LLP (Nominated Adviser and Broker)	+44 (0)20 3470 0470
---	---------------------

Matthew Johnson / Charlie Bouverat (Corporate Finance) Vadim Alexandre / Rob Rees (Corporate Broking)	
--	--

Deutsche Numis (Joint Broker)	+44 (0)20 7260 1000
-------------------------------	---------------------

Freddie Barnfield / Duncan Monteith / Michael Palser	
--	--

Allegra Finance (French Listing Sponsor)  
Rémi Durgetto / Yannick Petit

+33 (1) 42 22 10 10 r.durgetto@allegrafinance.com /  
y.petit@allegrafinance.com

---

Walbrook PR (Financial PR & IR)  
Stephanie Cuthbert / Anna Dunphy / Phillip Marriage

+44 (0)20 7933 8780  
novacyt@walbrookpr.com

---

## About Novacyt Group

Novacyt is an international diagnostics business delivering a broad portfolio of in vitro and molecular diagnostic tests for a wide range of infectious diseases, enabling faster, more accurate, accessible testing to improve healthcare outcomes. The Company provides customers with a seamless sample-to-result workflow using its integrated and scalable instrumentation/solutions. The Company specialises in the design, manufacture, and supply of real-time PCR kits, reagents and a full range of laboratory and qPCR instrumentation for molecular biology research and clinical use. Novacyt offers one of the world's most varied and comprehensive range of qPCR assays, covering human, veterinary, biodefence, environmental, agriculture and food testing.

The acquisition of Yourgene in September 2023 added a complementary international genomics technology and services business, focussed on delivering accurate molecular diagnostic and screening solutions, across reproductive health and precision medicine. Yourgene's portfolio of in vitro diagnostic products includes non-invasive prenatal tests (NIPT) for Down's Syndrome and other genetic disorders, Cystic Fibrosis screening tests, invasive rapid aneuploidy tests and DPYD genotyping assays. Yourgene also works in partnership with global leaders in DNA technology to allow its Ranger® Technology to deliver dynamic target enrichment.

Novacyt is headquartered in Vélizy in France with offices in the UK in Stokesley, Eastleigh and Manchester. The Company also has offices in Taipei (divestment pending), Singapore, the US and Canada and is listed on the London Stock Exchange's AIM market ("NCYT") and on the Paris Stock Exchange Euronext Growth ("ALNOV").

For more information, please refer to the website: [www.novacyt.com](http://www.novacyt.com)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rns@lseg.com](mailto:rns@lseg.com) or visit [www.rns.com](http://www.rns.com). RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

RAGXQLFLXBLEFBD